Clinical and Laboratory Predictors of Relapse within One Year after Omalizumab Discontinuation in Chronic Spontaneous Urticaria: A Real-Life Cohort Study
International Archives of Allergy and Immunology · 2025
DOI: 10.1159/000549643 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift International Archives of Allergy and Immunology, 2025. Verfasst von Ferhat Sağun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Immunology and Allergy, Department of Internal Medicine, Necmettin Erbakan University Faculty of Medicine, Konya, Turkey. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Anti-Allergic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Introduction
Relapse after omalizumab discontinuation in chronic spontaneous urticaria (CSU) is frequent, but predictors of recurrence remain unclear. This study aimed to identify clinical and laboratory factors associated with relapse within 12 months after treatment withdrawal.
Methods
We retrospectively analyzed 176 adult CSU patients who received omalizumab for ≥6 months and were followed for ≥12 months after discontinuation. Demographic, clinical, and laboratory variables were compared between relapse and non-relapse groups using logistic regression analyses.
Results
Relapse occurred in 118 patients (67.0%) within 12 months after omalizumab discontinuation. In multivariable analysis, three variables were independently associated with relapse: lower baseline Urticaria Control Test (UCT) score (odds ratio [OR] per 1-point increase = 0.60; 95% confidence interval [CI]: 0.47–0.77; p < 0.001), longer time to response after omalizumab initiation (OR per month = 2.64; 95% CI: 1.36–5.12; p = 0.004), and a history of prior relapse after treatment withdrawal (OR = 9.80; 95% CI: 1.52–63.14; p = 0.016). In univariate analysis, urticaria duration was significantly longer in relapsing patients (p < 0.001), but it was not an independent predictor. Additionally, no independent associations were found for age, sex, treatment duration, total immunoglobulin E, anti-thyroid peroxidase antibody, or comorbidities (all p > 0.05). The multivariable model showed excellent discrimination (area under the curve = 0.90; 95% CI: 0.84–0.95).
Conclusion
Lower baseline disease control, delayed clinical response, and prior relapse history were independent predictors of recurrence within 12 months after omalizumab discontinuation, whereas treatment duration and routine serologic markers were not. These findings highlight the need for individualized discontinuation strategies in CSU management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Immunology and Allergy, Department of Internal Medicine, Necmettin Erbakan University Faculty of Medicine, Konya, Turkey.
- Division of Clinical Immunology and Allergy, Department of Internal Medicine, Necmettin Erbakan University Faculty of Medicine, Konya, Turkey, neueriskinimmunoloji@gmail.com.
Zitieren
APA
Sağun, F., Çölkesen, F., Gerek, M. E., Kolak, S., Harman, E., Aslan Savaş, Ş., Yiğitdöl, İ., Yılmaz Ergün, Ü., & Arslan, Ş. (2025). Clinical and Laboratory Predictors of Relapse within One Year after Omalizumab Discontinuation in Chronic Spontaneous Urticaria: A Real-Life Cohort Study. International Archives of Allergy and Immunology. https://doi.org/10.1159/000549643
Vancouver
Sağun F, Çölkesen F, Gerek ME, Kolak S, Harman E, Aslan Savaş Ş, et al. Clinical and Laboratory Predictors of Relapse within One Year after Omalizumab Discontinuation in Chronic Spontaneous Urticaria: A Real-Life Cohort Study. International Archives of Allergy and Immunology. 2025. doi:10.1159/000549643
BibTeX
@article{Saun2025,
author = {Sağun, Ferhat and Çölkesen, Fatih and Gerek, Mehmet Emin and Kolak, Seçim and Harman, Emrah and Aslan Savaş, Şükran and Yiğitdöl, İsmail and Yılmaz Ergün, Ümmügülsüm and Arslan, Şevket},
title = {Clinical and Laboratory Predictors of Relapse within One Year after Omalizumab Discontinuation in Chronic Spontaneous Urticaria: A Real-Life Cohort Study},
journal = {International Archives of Allergy and Immunology},
year = {2025},
doi = {10.1159/000549643}
}
EUVIMED